Vasopressin and ethanol preference. II. Altered preference in two strains of diabetes insipidus rats and nephrogenic diabetes insipidus mice

In the first paper of this series, the influence of a single gene (di) for vasopressin deficiency on ethanol intake in rats was demonstrated. We studied preference for concentrations of ethanol between 2.2 and 10 percent versus tap water in Brattleboro rats homozygous for diabetes insipidus (di/di), heterozygous (di/+) or normal (+/+). The di/di rats, totally lacking in vasopressin, had greatly reduced preference scores for all concentrations of ethanol. Their intake of ethanol (g/day) was higher than heterozygotes or normals, but only when 2.2 percent ethanol was offered as a choice. Treatment with vasopressin or related peptides restored ethanol drinking to normal but also corrected water balance. In the experiments reported here, Roman High Avoidance (RHA) rats of three genotypes (+/+, di/+, and di/di) were also tested for ethanol intake and preference with similar but not identical results. Thus, the effects of the di gene are independent of the genetic background on which it is placed to at least some extent. Chlorothiazide, a drug unrelated to vasopressin, also normalized ethanol drinking and corrected water balance in di/di rats. In nephrogenic diabetes insipidus mice, there was a strong negative correlation between severity of polydipsia and preference for ethanol. Thus, no paradigm tested was effective in dissociating polydipsia from reduced ethanol preference and increased ethanol intake. While these results cannot exclude a possible regulatory role for endogenous vasopressin in ethanol preference drinking, they more strongly suggest that reduced preference for ethanol and increased ethanol intake are epiphenomena secondary to a polydipsic state.     

A POLAROGRAPHIC METHODOLOGY FOR CONTINUOUS NON-DESTRUCTIVE MONITORING OF DRUG RELEASE FROM LIPOSOMES

A simple methodology based on the differential pulse polarography (DPP) was developed for non-destructive monitoring of drug release from liposomes. The methodology was also capable of determining not only the released material that remained free in the liposomal suspension but also the amount of the drug which was eventually adsorbed on the vesicles surface after its release from the liposomes. Based on this methodology the release kinetics of encapsulated chlorothiazide in 5 mg ml^?1 DRV liposomes was studied at 37°C at pH 7.4. The results were compared to those obtained by centrifuging the DRV sample and measuring the free drug in the supernatant solution with UV-spectroscopy. Approximately 70% of the initially encapsulated drug were released within 24 h of which ca. 46% were subsequently adsorbed on vesicles' surface.